Zentiva, a leading pharmaceutical company headquartered in the Czech Republic (CZ), has established itself as a key player in the generic and specialty medicines sector since its founding in 2003. With a strong presence across Europe, Zentiva focuses on delivering high-quality, affordable healthcare solutions that cater to diverse patient needs. The company’s core offerings include a wide range of generic medications, over-the-counter products, and specialty pharmaceuticals, all designed to enhance patient access to essential treatments. Zentiva is recognised for its commitment to quality and innovation, ensuring that its products meet rigorous industry standards. Notable achievements include expanding its operational footprint in major European markets, positioning Zentiva as a trusted partner in healthcare. With a dedication to sustainability and patient-centric solutions, Zentiva continues to make significant strides in the pharmaceutical industry.
How does Zentiva's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Zentiva's score of 83 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Zentiva reported total carbon emissions of approximately 411,860,000 kg CO2e. This includes 13,722,000 kg CO2e from Scope 1 emissions, 14,088,000 kg CO2e from Scope 2 emissions (market-based), and a significant 384,050,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (about 308,083,000 kg CO2e) and upstream transportation and distribution (approximately 19,344,000 kg CO2e). Comparatively, in 2023, Zentiva's total emissions were about 81,444,000 kg CO2e, with Scope 1 at 15,038,000 kg CO2e, Scope 2 at 13,607,000 kg CO2e (market-based), and Scope 3 at 52,799,000 kg CO2e. This indicates a substantial increase in emissions from 2023 to 2024. Zentiva's emissions data is cascaded from its parent company, Sanofi, reflecting a corporate family relationship. However, there are currently no specific reduction targets or climate pledges disclosed by Zentiva. The company is committed to sustainability initiatives, but detailed reduction strategies or targets have not been provided in the available data.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 20,652,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 13,171,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 44,607,000 | 00,000,000 | 00,000,000 | 000,000,000 |
Zentiva's Scope 3 emissions, which increased by 627% last year and increased by approximately 761% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 80% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Zentiva has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.